1. Introduction {#S1}
===============

Identifying the mechanisms whereby neurodegenerative disorders progress throughout the brain is of critical importance both for the development of early diagnostic methods and for impeding disease progression. The occurrence of olfactory perceptual deficits in neurological disorders has been characterized for decades, and it is clear that in many of these disorders, olfactory deficits appear early, sometimes preceding the classical cognitive and motor symptoms ([@R8]; [@R29]; [@R122], [@R123]; [@R220]). In some cases, olfactory dysfunction is unique during disease onset while other sensory systems are spared (e.g., [@R167]; [@R302]), suggesting that the olfactory system might, to some extent, be particularly vulnerable to some neurological disorders. Little is known about why these disorders affect the olfactory system early. It is also unclear which of all of the pathogens in each of these disorders are responsible for the olfactory impairments. Lastly, the mechanisms by which disease-associated pathogens exert their influences upon olfactory neurons are unknown.

We and others have predicted that the olfactory bulb (OB)---the first stage of olfactory system processing and in close contact with the external world---serves as an entry point for pathogens or an access point for environmental insults, which can trigger pathological changes that then can spread throughout the brain via olfactory pathways ([@R106]; [@R124]; [@R212]). Since these neurodegenerative disorders involve proteinaceous pathogens, this prediction is in accord with the prion hypothesis, which states that by spreading in the brain and acting as templates for endogenous proteins to form pathological aggregates, misfolded proteins resistant to degradation are responsible for disease ([@R3]; [@R178]; [@R342]; [@R358]). Indeed, OB pathology is prevalent in the early stages of some neurological disorders (e.g., ([@R52]; [@R53]; [@R430]; [@R494]). We need to determine whether or not the OB is starting point for pathology and whether aberrant molecular changes there are capable of triggering the spread of protein aggregates throughout the brain. Such knowledge will be crucial for resolving the fundamental biology of neurological diseases.

In this review, we summarize what we know of the relationships between olfactory system function and neurological disorders including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), and others. We also review evidence for the roles of specific pathogenic features in these relationships. We discuss possible ways that olfactory pathology might be triggered in the olfactory bulb and spread throughout the brain. Finally, we synthesize concepts to support the theory that the OB is a starting point for prion-like pathogenic spread throughout the brain.

2. Olfactory dysfunction is common in many neurodegenerative diseases {#S2}
=====================================================================

Olfaction is an overarching term which implies several distinct abilities, i.e. odor detection, odor discrimination, odor memory, and odor identification (with or without a language component). Olfactory dysfunction develops with normal aging ([@R50]; [@R261]; [@R382]), and 6--16% of presumed healthy elderly are affected ([@R382]). In neurodegenerative diseases, the percentage of people exhibiting olfactory deficits frequently exceeds 90%, depending on the disease ([@R168]; [@R194]; [@R246]). The difficulty in interpreting data on olfactory dysfunction in healthy aging is that elderly people who are assumed to be healthy but have olfactory deficits could be in the early stage of an undiagnosed neurodegenerative disease. Tests of olfactory function have been included as part of the battery of diagnostic tools for PD and AD ([@R122]; [@R307]; [@R488]). In the following sections, we describe olfactory dysfunction in neurodegenerative diseases, with a focus on PD and AD and brief descriptions of other important neurodegenerative conditions in which olfactory deficits are prevalent.

2.1. Parkinson's disease and other related synucleinopathies {#S3}
------------------------------------------------------------

While olfactory dysfunction has been well studied in PD, data from other synucleinopathies are limited. Here we cull the most important observations in PD and review literature on other synucleinopathies.

### 2.1.1. Parkinson's disease {#S4}

Olfactory deficits in PD, first identified by [@R11], are considered as one of the earliest neurological signs of PD, preceding the appearance of the classical motor deficits by at least 4 years ([@R8]; [@R19]; [@R122], [@R123]; [@R136]; [@R185]; [@R210]; [@R352]; [@R378], [@R379]). Only rarely are PD patients normosmic ([@R380]). Olfactory dysfunction is present both in familial and sporadic PD ([@R122]) and occurs in more than 90% of cases ([@R122]; [@R129]; [@R201]). These observations are consistent despite the use of different olfactory tests across more than 100 studies published since 1980 ([@R123]). These tests mainly probed olfactory discrimination and odor identification ([@R132], [@R133], [@R134]), but odor detection and odor memory were also assessed. Olfaction was proposed as a diagnostic criterion for prodromal PD by the International Parkinson and Movement Disorder Society (MDS) ([@R354]).

Anosmia (total loss of the sense of smell) occurs only in a small minority of PD patients, while hyposmia (reduced sense of smell) is more common ([@R129]). PD patients also have deficits in odor detection, discrimination, and identification ([@R122]; [@R129], [@R127]; [@R217]; [@R252]; [@R497]), as well as in odor hedonicity (perception of pleasantness) ([@R217]; [@R322]). Mild deficits in odor recognition have been described in PD, but it is unclear if they instead were really due to defective detection ([@R46]). Odor identification deficits affect 82--90% of PD patients ([@R83]). These deficits are summarized in [Table 1](#T1){ref-type="table"}.

The origin of olfactory loss in PD remains poorly understood, but it is believed to relate both to low- and high-order olfactory impairments. About 80% of PD patients have abnormal olfactory evoked responses ([@R32]; [@R194]; [@R199]). Indeed, even detection threshold, which largely requires a lower level of perceptual processing, is impaired in PD. This is supported by observations that increased sniffing volume improves olfactory scores in PD ([@R418]). Further, odor identification, which is considered by some dependent on central processing, is severely affected in PD ([@R204]; [@R263]; [@R365]).

Protein inclusions, inflammation in olfactory regions, and alterations in neurotransmitter systems probably play important roles in PD-related olfactory dysfunction. The great number of Lewy bodies (LBs) and Lewy neurites (LNs) in olfactory structures (described further below) could be partly responsible for the alteration of olfactory processing. People without PD who exhibit LBs in the entorhinal cortex and substantia nigra show olfactory identification deficits prior to death ([@R479]). This supports the idea that LBs outside motor brain regions negatively affect central olfactory processing. However, there is evidence that LBs are found in the olfactory bulb and olfactory tract of virtually all PD subjects ([@R34]). The effects of peripheral olfactory pathology (e.g., in the olfactory epithelium, OE) on olfactory loss have not yet been defined ([@R479]). In addition, tau pathology observed in the anterior olfactory nucleus (AON) of PD patients could also contribute to olfactory deficits ([@R122]; [@R444]). Olfaction is also mildly impaired In incidental Lewy body disease (iLBD; deceased individuals who have LBs in the brain but had no PD symptoms), which is thought to represent prodromal PD or a forerunner of other synucleinopathies ([@R2]; [@R138]; [@R378]).

Numerous studies have investigated whether olfactory loss could be a biomarker for motor dysfunction or cognitive impairments. The earliest cross-sectional studies suggested that olfactory dysfunction in PD is stable over time ([@R129]; [@R363]); thus, it does not clearly correlate with severity of the motor dysfunction or disease stage. It is also not influenced by standard anti-parkinsonian treatments ([@R136]), although a recent study suggested that the monoamine oxidase B inhibitor rasagiline might improve odor discrimination in early stage PD ([@R184]). Recent investigations suggest a slight worsening of olfactory function over time ([@R37]; [@R439]), and marked changes in olfactory threshold and odor discrimination alterations correlate with more rapid disease progression ([@R11]; [@R83]; [@R194]; [@R439]). Other studies have suggested that poor olfactory scores in PD correlate with dementia scores ([@R8]; [@R21]; [@R105]; [@R267]; [@R379]). In one study, only PD patients with severe hyposmia and mild cognitive impairments developed severe dementia after 3 years, suggesting that severe hyposmia is associated with increased dementia risk ([@R8]; [@R21]). A recent study demonstrated that in a large cohort of newly diagnosed people with PD, aside from high age, hyposmia and sleep disorder were the two strongest predictors, of a range of measures, that cognitive decline would develop two years later ([@R400]). A different longitudinal study described unpredictable variations in olfactory function, possibly coupled to fluctuations in dopaminergic activity in the OB ([@R210]). Progressive degeneration of the cholinergic, noradrenergic, and serotoninergic neuromodulatory systems innervating olfactory structures has been suggested to correlate with olfactory loss in PD (for review, ([@R122])).

Olfactory dysfunction has not been studied extensively in familial PD, and there appears to be great heterogeneity depending on the mutation ([@R122]). Two patients of eight carrying the A53T mutation of the α-synuclein (α-syn) gene (G209 on exon 4) exhibited anosmia ([@R49]), while no signs of olfactory deficits were detected in carriers of the α-syn E46K mutation ([@R254]; [@R438]). Several reports suggest that cases of autosomal recessive PD due to parkin mutations are normosmic ([@R6]; [@R243]; [@R294]). By contrast, patients with *pink1* mutations have changes in odor identification, detection, and discrimination ([@R151]). Patients with the most common monogenetic form of PD, i.e., those with mutations of the *LRRK2* gene ([@R122]; [@R152]; [@R242]; [@R393]; [@R412]; [@R448]) have olfactory deficits similar to or more severe than idiopathic cases ([@R393]; [@R412]). Two of three studies describe altered olfaction in *LRRK2* mutation carriers prior to signs of PD ([@R229]; [@R242]; [@R393]). Finally, individuals with heterozygous *GBA* mutations ([@R123]; [@R171]; [@R392]), who have a six-fold greater risk of PD ([@R404]), exhibit impaired olfaction after the appearance of motor deficits. In one case with a *GBA* mutation, it was reported that loss of olfaction occurred 30 years before the onset of PD motor symptoms ([@R392]). It is notable that olfactory dysfunction is not highly common in some atypical Parkinsonian disorders ([@R193]; [@R229]; [@R294]).

### 2.1.2. Dementia with Lewy bodies {#S5}

In dementia with Lewy bodies (DLB), where dementia is the presenting symptom and motor deficits typically appear within a year ([@R488]), severe olfactory deficits are seen, akin to PD ([@R166]; [@R275]; [@R301]; [@R337]; [@R479]) DLB patients exhibit higher prevalence of and more severe olfactory deficits than Alzheimer's disease (AD) patients (described in a later section) ([@R90]; [@R337]; [@R391]; [@R471]; [@R473]). Therefore, in individuals presenting with minimal cognitive impairment, more severe olfactory deficits are predictive of conversion to DLB versus to AD ([@R488]). The olfactory deficits are often apparent in early DLB, and might also be considered part of the emerging concept of prodromal DLB ([@R299]).

2.2. Alzheimer's disease {#S6}
------------------------

Typically, AD is (though not invariably ([@R470])) characterized by a progressive worsening of olfactory function. Plentiful reports describe the types of olfactory impairments and how they correspond to AD stages. Here we summarize a selection of those reports to highlight the basic aspects of olfactory dysfunction in AD and their possible origins.

Deficits in odor detection, recognition, discrimination, and long-term odor recognition memory have been reported (e.g., ([@R125]; [@R317]; [@R324]; [@R403])) with a prevalence of 90--100% ([@R19]; [@R140]), and they appear before cognitive impairment ([@R117]). A meta-analysis of studies on olfactory function in AD reported that, in comparison to age-matched controls, AD patients displayed greater deficits in odor detection thresholds, identification ability, and recognition ([@R304]). Olfactory dysfunction appears in early stages of AD (as in PD) and precedes the clinical manifestations of minimal cognitive impairment and AD ([@R478]). Impairments of odor discrimination and identification are more severe than those of odor detection ([@R159]). The overall severity of olfactory deficits in AD is equivalent to those in PD, but PD patients exhibit more severe impairment of detection threshold. This suggests that AD patients are more affected in higher-order olfactory tasks ([@R365]).

Some genetic factors possibly contributing to the olfactory deficits have begun to emerge, one being the presence of one or two copies of the e4 allele of apolipoprotein E, an established risk factor for spontaneous AD ([@R167]). Other factors, found in preclinical mouse models, are the presence of mutations in the amyloid precursor protein (APP) gene ([@R88]; [@R180]; [@R468]) or the overexpression of the human tau protein ([@R292]).

Most evidence to date suggests that olfactory abnormalities in AD are due to central sensorineural dysfunction more than to the inability of odor information to enter the brain ("conductive" dysfunction). First, as detailed below, central olfactory structures can be greatly burdened with AD pathology during later disease stages (e.g., ([@R53])). Lower odor identification test scores are associated with higher levels of AD pathology in central olfactory structures ([@R478]), although AD pathology is also observed in the OE ([@R15]). These data suggest that the neuroanatomical underpinnings of olfactory impairments in AD versus PD are to some extent different. Second, the hallmark perceptual deficits of reduced discrimination and recognition of odors implies that odor information at least enters the brain in AD. Third, measures of central olfactory physiology, including event-related olfactory potentials measured by scalp EEG ([@R167]; [@R316]), functional MRI ([@R273]), and local field potentials ([@R467]), reveal a variety of central processing deficits in both humans and mice, some of which can be attributed to genetic variations associated with AD risk ([@R167]; [@R316]; [@R467]) Finally, the early loss of noradrenergic neurons in the locus coeruleus and cholinergic neurons in the nucleus basalis of Meynert in AD ([@R296]), which modulate olfactory activity ([@R104]; [@R137]; [@R179]; [@R295]; [@R455]; [@R475]), could also severely impact olfaction ([@R108]; [@R370]).

In light of the progressive worsening of olfactory dysfunction in AD, numerous studies have proposed olfactory dysfunction as a predictive biomarker for the disease. In one study, combining olfactory function scores with other biomarkers for AD (e.g., entorhinal cortex volume, amyloid-beta cerebral spinal fluid levels, verbal memory) enhanced the diagnostic accuracy for predicting persons who would progress from mild cognitive impairment (MCI) to AD ([@R117]) Further, in aged individuals without MCI or AD, evidence suggests that olfactory dysfunction is related to the level of AD pathology and the risk for developing further prodromal AD symptoms ([@R478]). Finally, event-related olfactory potentials measured by EEG are aberrant in non-demented individuals who are positive for the apolipoprotein E E4 allele ([@R316]). Thus, olfactory dysfunction might serve as an early biomarker of AD even prior to detectable dementia or MCI.

Interestingly, similar impairments in odor detection thresholds, identification, and recognition were found between the AD and PD groups in meta-analysis ([@R304]). While this presents clear difficulty in differentiating between these disorders based upon olfaction alone, these commonalities may illuminate core principles of dysfunction in the two disorders.

2.3. Examples of other neurodegenerative diseases with olfactory deficits {#S7}
-------------------------------------------------------------------------

Several diseases with parkinsonian syndrome that can be mistaken for PD have either no or slight olfactory deficits ([@R123]). This is the case for essential tremor ([@R12]; [@R74]; [@R195]; [@R283]; [@R360]; [@R428]) and for the early stages of the X-linked recessive dystonia-parkinsonism ([@R146]). Only mild deficits in odor identification are described in corticobasal degeneration (CBD) ([@R289]; [@R466]) and multiple system atrophy (MSA; for both the subtypes MSA-P and MSA-C) ([@R1]; [@R163]; [@R173]; [@R244]; [@R325]; [@R328]; [@R426]; [@R465]). Consequently, olfactory testing is helpful for differential diagnosis between PD and other diseases with Parkinsonism ([@R74]; [@R130], [@R135], [@R128]; [@R466]).

Numerous non-parkinsonian neurodegenerative diseases exhibit mild to severe olfactory dysfunction. Odor identification is impaired in the frontal variant of FTD (prevalence 96%) ([@R211]; [@R289]; [@R300]; [@R341]), in ALS (prevalence 75%) ([@R4]; [@R144]; [@R200]; [@R432]), in some patients with multiple sclerosis ([@R286]), and in Huntington's disease ([@R75]; [@R187]; [@R265]). Other olfactory abilities have not been systematically assessed, but deficits in odor recognition and memory odor detection are described in HD ([@R30]; [@R187]; [@R333]; [@R350]), in a new variant of CJD ([@R368]), and in multiple sclerosis (depending on the location of the demyelinating lesions) ([@R31]; [@R99]; [@R131]; [@R272]; [@R286]; [@R288]). Further, in HD, altered perception of odor hedonicity ([@R310]) and other olfactory deficits precede cognitive deficits and involuntary movements ([@R262]; [@R311]). It is interesting that all non-parkinsonian diseases are associated with olfactory deficits, while only PD and DLB of the parkinsonian diseases have such deficits (a non-exhaustive summary is presented in [Table 1](#T1){ref-type="table"}).

3. The olfactory system {#S8}
=======================

In this section, we briefly describe the anatomy and physiology of the olfactory rostral structures, the olfactory mucosa and the OB. Given the extensive anatomical literature arising from rodent-based investigations, most of the descriptions herein are from rat and mouse studies.

3.1. Neuronal organization of the olfactory mucosa and olfactory bulb {#S9}
---------------------------------------------------------------------

The OB is a six-layer structure in which the sequential stages of odor information processing take place. In all terrestrial vertebrates, nasal airflow (e.g., sniffing) carries odorants into contact with olfactory receptors (ORs) located on the cilia of olfactory receptor neurons (ORNs) in the nasal olfactory mucosa ([Fig. 1](#F1){ref-type="fig"}). Odorant binding with an OR triggers a G-coupled protein--mediated intracellular signaling cascade, ultimately producing an action potential ([@R489]). The ORs possess unique tuning profiles ([@R13]; [@R44]) that provide a first step at which the olfactory system can sort the essentially limitless number of odorants it may encounter.

The soma of ORNs is located in the OE, and their axons fasciculate and pass through the cribriform plate ([Fig. 1](#F1){ref-type="fig"}), where they then form the olfactory nerve layer of the OB. In mammals, ORNs express only one OR type ([@R89]), and ORNs expressing the same OR innervate two glomeruli per OB ([@R312]). Thus, in this arrangement, action potentials in the ORNs relay odorant information into discrete zones in the OB whose activation is dictated by nasal airflow ([@R71]; [@R321]; [@R454]). The spatio-temporal zones formed across the OB can be plotted to form a "spatial map" of odorant information ([@R231]; [@R405]; [@R420]; [@R446]) and are modulated by local glomerular layer neurons (including periglomerular, short axon, and external tufted cells) a process thought important for the most basic aspects of olfactory perception, including odor recognition and discrimination ([@R20]; [@R202]; [@R460]).

Secondary olfactory neurons, called mitral cells (MCs) and tufted cells (TCs), innervate glomeruli, where they receive postsynaptic glutamatergic input from ORNs. The cell body of MCs are located in the mitral cell layer of the OB, whereas the cell body of TCs reside in the external plexiform layer. While both cell types are similar in their reception of monosynaptic odor information from ORNs and their lateral dendrite arbors, they have different physiological responses to odors, including odor intensity coding ([@R326]; [@R396]). The MCs and TCs provide bisynaptic information into downstream secondary olfactory (cortical) structures, as described below.

An additional major cell type in the OB is the granule cell. Granule cells are found in the most central OB cell layer and can be identified as small axon-less cells organized in patchy aggregated rows. The apical dendrites of granule cells synapse upon, and are synapsed upon by, MTs and TCs. Granule cells also receive centrifugal input from some secondary olfactory structures. Granule cells display broader odor-tuning characteristics than the upstream MCs and TCs ([@R433]).

Granule cells (GABAergic and glutamatergic) are constantly renewed by neurogenesis during adulthood in many mammalian species, and they derive from neuroblasts originating from the subventricular zone of the anterior forebrain that migrate to the OB. There they differentiate and integrate into the granular and glomerular layers of the OB ([@R7]; [@R65]; [@R223]; [@R281]; [@R282]). The magnitude and importance of olfactory neurogenesis in human remain debated ([@R39]; [@R103]; [@R230]; [@R285]; [@R291]; [@R389]) and could be limited ([@R38]; [@R215]).

The activity of MCs, TCs, and interneurons in the OB is subject to neuromodulation (for a review, see ([@R278])). The OB receives dense noradrenergic projections from the locus coeruleus, cholinergic input from the horizontal limb of diagonal band of Broca, and serotoninergic afferents from the medial and dorsal raphe nuclei. Of particular interest to PD, dopamine is synthesized locally in the OB by dopaminergic interneurons of the periglomerular layer ([@R23]). Interestingly, these interneurons are reported to be greater in number in PD patients compared to age-matched controls ([@R218]). In addition, a minor input to the OB from dopa-minergic neurons in the substantia nigra was recently described in rats ([@R214]). Additional details on the function of OB circuits can be found elsewhere ([@R319]; [@R406]; [@R477]).

3.2. Neuronal connections within the olfactory system and with the rest of the brain {#S10}
------------------------------------------------------------------------------------

Axons from MC and TC fasciculate to form the lateral olfactory tract, from which their distal projections branch and innervate a variety of secondary olfactory structures. Indeed, unlike other sensory networks, the olfactory system bypasses the thalamus for cortical integration of olfactory information; instead, MCs and TCs directly innervate these secondary olfactory structures. Secondary olfactory structures include the anterior olfactory nucleus (AON), piriform cortex, olfactory tubercle, the lateral entorhinal cortex, and others, which receive monosynaptic input from MCs or TCs. While it is thought these structures, unlike the OB, contribute to more perceptually or behaviorally relevant aspects of olfaction, the unique contributions of these secondary structures to olfaction are mostly undefined ([@R70]; [@R176]; [@R469]; [@R476]). Here we summarize the known aspects of some of these structures.

Located in the basal forebrain, the AON is a layered structure composed of several subdivisions which receive dense MC and TC innervation ([@R305]) and whose cells display odor responsivity ([@R240]). A distinct feature of the AON is its contralateral projection system wherein principal neurons of the AON span the midline of the brain and innervate the contralateral AON ([@R222]). This contralateral projection system is thought to aid in intra-nostril odor localization ([@R245]). The AON also provides centrifugal modulation of sensory processing in the OB and itself is subject to neuromodulation ([@R334]; [@R381]).

The piriform cortex is well established for its roles in modifying the processing of odors based upon experience and learning ([@R28]; [@R176]; [@R397]; [@R476]). Pyramidal cells in the piriform cortex receive odor input via MCs and TCs, and pyramidal cell association fibers modulate odor representations both among the piriform cortex neural ensembles and in connected structures ([@R80]; [@R82]; Haberly and Price, 1978a; [@R279]). In rats, piriform cortex neurons display profound adaptation to prolonged or repeated odor exposure ([@R474]). Further, the piriform cortex possesses anatomically defined zones which differentially represent odor components versus synthetic odor images such as those which evolve after learning or those perceived when smelling complex odorant mixtures ([@R235]).

While the olfactory tubercle receives dense TC input from the OB, making it a secondary olfactory structure, the olfactory tubercle is unique among olfactory structures in that it is a component of the ventral striatum ([@R111]; [@R469]). This provides the olfactory tubercle with privileged connection with basal ganglia. Also unlike other secondary olfactory structures, the olfactory tubercle does not possess an association-fiber system ([@R183]). Similar to neurons in the AON and piriform cortex, olfactory tubercle neurons represent odor information ([@R78]; [@R344]; [@R468]; [@R485]) and can do so in manners dependent upon the behavioral state of animals. Thus, olfactory tubercle neurons robustly reflect odor valence, the occurrence of motivated behaviors, and even the acquisition of rewards, suggesting important roles for the olfactory tubercle in guiding hedonic and valence-dependent responses to odors ([@R160]; [@R161]).

Neurons within secondary olfactory structures project into tertiary olfactory structures, including the orbitofrontal cortex, the insular cortex, and the dorsal hippocampus ([@R126]). Of particular relevance to AD, the entorhinal cortex innervates the hippocampus via the perforant pathway ([@R175]). Additionally, thalamic regions receive olfactory information from several of the secondary olfactory structures, including the AON, piriform cortex, and olfactory tubercle. Olfactory information is also transmitted to the hypothalamus via the amygdaloid complex ([@R126]).

Neural activity in secondary olfactory structures is subject to neuromodulation, like such activity in the OB (for review see ([@R278])). For instance, AON activity in mice is modulated by oxytocin ([@R334]). The activity of the piriform cortex is shaped by cholinergic input from the horizontal diagonal band ([@R280]). In rats, the activity of the olfactory tubercle is further shaped by the activation of neurons in the ventral tegmentum ([@R313]), which release dopamine among other neurotransmitters.

In summary, the olfactory system exhibits a highly complex network of reciprocal, centripetal, centrifugal, and associative connections, and it bridges numerous brain regions involved in many neurodegenerative diseases. Since all of the secondary olfactory structures are densely interconnected with not only each other but also other non-olfactory brain regions, they may provide a conduit for pathogens from the OB into more central brain structures needed for cognition, movement, and other crucial functions.

3.3. Glial and support cells organization in the olfactory mucosa and bulb {#S11}
--------------------------------------------------------------------------

Glial and support cells of the olfactory mucosa and OB play an essential role in protecting brain structures against external insults and in sustaining neurons for proper transduction of odorant stimuli into olfactory input.

The olfactory mucosa (OE and lamina propria) includes supporting cells and horizontal and globose basal cells, which are located within the OE in a columnar organization. The supporting or sustentacular cells display fine cellular extensions that are in contact with ORNs. The apex of such cells extends dense, long microvilli into the nasal lumen, where they are in direct contact with mucus and can interact with the cilia of ORNs ([@R126]) ([Fig. 1](#F1){ref-type="fig"}). These sustentacular supporting cells have multiple roles: they maintain water and salt balance in the mucus and provide electrical insulation to ORNs. Additionally, the supporting cells are able to metabolize (detoxify) inhaled toxicants and may be involved in removing debris of dying cells, acting as phagocytes ([@R126]). With age and with intranasal viral infections, the number of ORNs, cilia, and supporting cell microvilli decreases dramatically. Similar structural alterations of the OE have been observed in AD and PD ([@R66]).

The horizontal basal cells in the OE sit on the lamina propria and slowly divide into globose cells, which are located above them, and give rise to new ORNs. Microvillous cells are present in low numbers and their function is still unclear (therefore not shown in [Fig. 1](#F1){ref-type="fig"}), but they can modulate the activity of ORNs and of supporting cells ([@R335]; [@R383]). The lamina propria of the olfactory mucosa includes Bowman's glands, composed of serous and stem cells that produce the mucus in which the olfactory cilia of the ORNs are immersed ([@R126]). This mucus contains odorant-binding proteins that aid in odorant absorption ([@R347]). It also contains immune factors (IgA, M, G), lysozymes, enzymes, and antioxidants, and it might contain xenobiotic-metabolizing enzymes that play an important role in viral inactivation, detoxification, bacterial degradation, and destruction of pro-inflammatory proteins ([@R119]). Thus, the mucus might protect the OE from external insults.

Finally, the axon bundles from the ORNs that traverse the cribriform plate are surrounded by ensheathing cells that have properties similar to those of Schwann cells and that are enveloped by fibroblasts. In the olfactory nerve fascicles, a specific population of microglia and macrophages halts the passage of viruses and xenobiotics to the brain ([@R417]). A dense population of glial cells, including a unique and abundant microglial population, is also present in the OB ([@R264]). Some have concluded that the microglia in the OB are in a constant "alert" state. They can sense an inflammatory response due to an injury taking place far from the OB and become activated as a consequence ([@R259]).

4. Neuropathology of the olfactory system in neurodegenerative diseases {#S12}
=======================================================================

The presence of protein inclusions in olfactory structures likely contributes significantly to the development of olfactory deficits in both normal aging and in age-related neurological conditions. Here, we review the neuropathological lesions in the olfactory system in the various neurodegenerative diseases which have been studied to date.

Considering the recent idea that misfolded proteins associated with neurodegenerative diseases can exhibit prion-like properties and propagate protein aggregation between brain regions from one neuron to another, it is crucial to understand where pathological protein inclusions appear first and which neural pathways they preferentially spread along. We review here the main neurodegenerative diseases that 1) involve α-syn, tau, Aβ, TDP-43, and prion inclusions and 2) where pathology and neurodegeneration are present in the olfactory system.

4.1. Lewy body diseases {#S13}
-----------------------

Lewy body disease progression is classified based on the localization of α-syn inclusions in the postmortem brain. A unified staging system proposes that the OB is the starting point of pathology in DLB, PD, and iLBD ([@R33]). From the OB, the pathology then progresses either to the brainstem or the limbic system at stage 2, to then converge to concomitant pathology in brainstem and limbic system at stage 3, and evolve finally to a neocortical stage ([@R33]). It is unclear whether or how the OE is involved in this timeline. The OE could be involved prior to the OB in PD, but it could also develop inclusions after the OB, which then would suggest retrograde propagation of the pathology from the OB to the OE.

### 4.1.1. Parkinson's disease {#S14}

Braak and colleagues defined six neuropathological stages for PD, based on α-syn inclusion (both LBs and LNs) localization. According to them, PD pathology progresses via neural connections from the OB to connected structures via the olfactory system, and from the dorsal motor nucleus of the vagal nerve (DMX) via the brainstem to cortical areas ([@R52], [@R59], [@R60], [@R61], [@R62]; [@R114]). LBs and Lewy neurites (LNs) composed mainly of misfolded α-syn, are detected first (Braak stage 1) in the OB, the AON ([@R62], [@R60]; [@R107]; [@R116]; [@R216]; [@R402]; [@R445]) and the vagal and glossopharyngeal nerves and nuclei ([@R52]; [@R116]). During stage 1, the inclusions are first found within non-AON areas of the human OB. They then appear in the AON and are present in the OB of patients displaying no α-syn inclusions in the DMX and any other brain region, indicating an earlier involvement of the OB than the DMX or AON ([@R55]; [@R113]; [@R402]). In the OB, α-syn inclusions are found in interneurons, in the internal plexiform layer ([@R122]), and less frequently in MCs and TCs, which raises the possibility that these relay neurons might be more resistant to developing α-syn aggregates than other neurons. A role of MCs and TCs in the propagation of pathology is, however, not excluded. MCs and TCs might better resist the development large α-syn aggregates (recognized in the microscope as Lewy pathology), but might allow more transfer of small seeds to connected regions.

In their original publications, [@R196], [@R197]) suggested that the agent causing Lewy pathology might be a neurotropic virus and that the OE was involved even earlier than the OB. At least four studies to date have investigated the presence of LBs and LNs in the olfactory mucosa ([@R139]; [@R158]; [@R386]; [@R480]). In one study, asymptomatic LBD patients who had Lewy pathology in the OB rarely displayed inclusions in the olfactory mucosa. Symptomatic patients presented LBs in their olfactory mucosa, but not in their OE ([@R158]), suggesting that the olfactory mucosa would be involved later than the OB. A more recent study from the same group, using a different dissection method that damages the OE less, describes Lewy pathology in ORNs of the OE and in the lamina propria of patients with PD, but it is unclear at which disease stage this occurs ([@R386]). Importantly, ORNs are renewed and have a high turnover (their median survival is 1--2 months); therefore, they might not have time to develop LBs and LNs, but they might still act as conduits for small aggregation-prone species of α-syn.

During stage 2, α-syn inclusions reach the locus coeruleus. In PD at Braak stages 3 and later, α-synuclein aggregates in the OB and AON become denser. At these stages, inclusions are also found in other secondary olfactory brain regions, principally the piriform cortex and cortical amygdala ([@R61], [@R60], [@R59], [@R54]; [@R190]; [@R409]), and to a lesser extent in the olfactory tubercle and entorhinal cortex ([@R114]; [@R216]; [@R445]). While the pathology is progressing to piriform, periamygdaloid, and entorhinal cortices, non-olfactory cortical regions remain intact ([@R60]; [@R115]; [@R197]). The olfactory tubercle and the nucleus of the lateral olfactory tract seem to develop α-syn aggregates later than other olfactory structures nearby ([@R114]). This might be interpreted as those structures being more resistant to aggregate pathology; an alternative interpretation is that the absence of projections from these structures to the OB reduces the risk of aggregate propagation, if retrograde axonal transport is crucial.

Regrettably, possible cell loss in the piriform cortex and in the OB (MCs and TCs) has never been investigated in PD brains. Severe cell loss occurs in the AON and correlates with severity of olfactory deficits ([@R345]). Significant neuronal loss also occurs in regions connected to the olfactory structures, namely, in the locus coeruleus (70%) ([@R41]; [@R165]) and to a lesser extent (30% loss) in the amygdala ([@R190]). As a result, the volume of the amygdala is reduced by 20% ([@R190]). The loss of volume in the amygdala and the piriform cortex inversely correlates with olfactory deficits ([@R464]), suggesting that cell loss in these regions could contribute to the functional deficits. The volume of the OB, the orbitofrontal cortex, and the piriform cortex is also decreased ([@R267]; [@R270]; [@R345]; [@R434]; [@R464]), suggesting possible cell loss in these brain regions as well. In addition, olfactory nerves in the olfactory tract undergo atrophy and lose their cellular architecture ([@R345]). Volumetric measurement of olfactory tracts can discriminate PD patients from controls ([@R377]; [@R395]).

Our recent work in mice using microinjections of preformed α-syn fibrils into the OB demonstrate that the olfactory route can be a vector of pathology spreading into the substantia nigra and other regions involved in later stages of PD ([@R371]), and this was confirmed by a second study ([@R297]). Specifically, we found that α-syn aggregates progressively spread from the OB to a total of over 40 different brain sub-regions bilaterally over the course of 12 months, and that the progressive development of synucleinopathy was coupled to the emergence of specific olfactory deficits ([@R371]). At the one year time point, there was evidence of very occasional α-syn aggregates in the substantia nigra in a few animals, inconsistent with a level believed necessary for nigral neurodegeneration to occur. Taken together, this mouse model is therefore considered to represent prodromal PD. Understanding that the pathology in the olfactory system precedes that in the substantia nigra opens new and important therapeutic avenues. Essentially, it should be possible to initiate future disease-modifying treatments in PD before the first motor symptoms occur. The time course of α-syn pathology propagation was protracted in the mice, and in view of the short normal lifespan of mice it can be viewed analogous to that suggested to occur in humans. In our study mice were injected at 3 months of age which is considered equivalent to around 20 years in humans, and at the final time point they were 15 months old, which is viewed to represent 50 years of age in humans (slightly younger than the median age of onset of PD). That said, we do not actually know how long it takes for α-syn aggregates to spread after they first develop in the OB in humans, as has been postulated to occur in PD. It is possible that the dynamics of α-syn aggregates spread observed in the mice is not dissimilar to humans, but that the size of the human brain (greater distances between nuclei and larger structures) require longer lag periods before significant levels of pathology are detected in downstream structures.

The notion that the propagation of α-syn pathology involves prion-like mechanisms has gained increased acceptance in recent years, and because it has been reviewed extensively in other articles we will not present all the details here (see e.g. ([@R112]; [@R164]; [@R170]; [@R239]; [@R287]; [@R369])). Briefly, this hypothesis posits that once α-syn aggregates have formed in a cell, some of them are excreted to the extracellular space. Once there, they are taken up by neighboring cells, including neurons, where they can seed the aggregation of endogenous α-syn through "permissive templating" by the misfolded α-syn species. Because misfolded α-syn can undergo axonal transport between brain regions, this hypothesis also accounts for how α-syn pathology spreads along, e.g., neural connections in the olfactory system. The realization that α-syn aggregates are present in the extracellular space during part of this pathogenic process, has led to suggestions that it might be possible to therapeutically target extracellular α-syn or, e.g., the molecular machinery involved in its cellular uptake ([@R112]). The possible existence of specific "strains" of α-syn fibrils has led to the proposal that pathobiological differences between the family of synucleinopathies (e.g. PD, DLB and MSA) are due to the properties of the α-syn fibrils that propagate between cells ([@R303]; [@R346]). It has been suggested that α-syn can directly cross seed tau ([@R181]), which could explain why tau aggregates also occur in synucleinopathies, but these observations of possible cross-seeding in mice remain debated.

### 4.1.2. Incidental Lewy body disease {#S15}

LB pathology does not appear to follow Braak staging in incidental Lewy body disease (iLBD). The OB exhibits Lewy pathology in 83% of cases ([@R402]), but only 1 patient out of 11 showed inclusions in the OE ([@R386]). In 77% of cases, LBs and LNs are also found in the AON, along with a minimal amount of neurofibrillary tangles (NFTs) ([@R444]). It has been proposed that iLBD constitutes prodromal PD, however, as mentioned above only some iLBD cases appear to be consistent with Braak staging, while others show pathology mainly in cortical regions, which could correspond to preclinical DLB (([@R156]); importantly the OB was not investigated in this study).

### 4.1.3. Dementia with Lewy bodies {#S16}

Similar to those with iLBD, patients with DLB frequently exhibit severe pathology in the OB. However, study of the olfactory mucosa in two recent cases found α-syn pathology only in the cribriform plate ([@R158]; [@R386]). Currently, the staging of PD and DLB relies on the presence of LBs or LNs. Novel methods allow the detection of oligomeric α-syn ([@R376]) and suggest that accumulation of oligomeric α-syn precedes the appearance of LBs and LNs. Investigating other forms of pathology might help us understand better the clinical variability in the pathology of synucleinopathies ([@R186]).

In addition to α-syn pathology, PD, DLB, and Parkinson's disease dementia (PDD) patients also display tau (neurofibrillary tangles) and Aβ pathology (senile plaques) ([@R209]; [@R213]; [@R268]). A limited overlap in pathology is thus observed between diseases. Tau pathology is observed notably in the OB/AON in cases of PD, AD, DLB, and FTD, which are diseases accompanied with severe olfactory alterations, but tau pathology is absent from PSP and CBD, two disorders with no or minor olfactory loss ([@R323]; [@R444]), suggesting a role for aggregated tau in the olfactory dysfunction of synucleinopathies.

4.2. Alzheimer's disease {#S17}
------------------------

In AD, brain regions critical to olfactory function are burdened with pathology, including the classic hallmark features of plaques and neurofibrillary tangles (NFTs). NFTs are made up of hyperphosphorylated forms of the microtubule-associated protein tau. Plaques are composed mainly of the amyloid precursor protein-derived amyloid-beta (Aβ). Similar to that for PD, a staging system in six neuropathological stages has been proposed by Braak and colleagues based on the localization of NFTs ([@R53]). According to this model, pathology is believed to start in the entorhinal cortex and spread to the hippocampus and then to the basal forebrain. While more recent models have proposed the locus coeruleus as the initial site of tau pathology in AD ([@R55], [@R56], [@R57]) the collective evidence for the entorhinal cortex and associated olfactory structures being affected early in the disease process remains compelling. Thus, the olfactory structures are affected early in AD (as in PD), prior to the appearance of cognitive symptoms ([@R17]; [@R228]; [@R356]). NFTs appear first in transentorhinal region and entorhinal cortex at stage 1, and progress to CA1 of the hippocampus at stage 2. Some studies describe tau pathology in all the layers of OB ([@R250]; [@R336]) and in the olfactory tract as early as the appearance of NFTs in the entorhinal cortex (stage 1) ([@R93]) or at stage 0 ([@R249]); some others at stage 2 only ([@R17]; [@R444]). Tau pathology is also present in the AON at early stages (([@R145]; [@R249]; [@R336]; [@R356]) (stages 0--1), ([@R444]) (stage 2), ([@R228]) (stage 2)). The periamygdaloid cortex and anterior amygdala are involved later, at or after stage 2 ([@R249]). The piriform cortex is also affected early by NFTs, possibly in early stages, but only one study has investigated it and no assessment of Braak stages were done ([@R373]). At Braak stage 3, NFTs develop in limbic regions (subiculum) and they progress to the amygdala and thalamus at stage 4. They later reach the isocortex (associative area) at stage 5 and ultimately affect the primary sensory, motor, and visual cortex at stage 6 ([@R53]). Tau aggregates, that make up the NFTs in AD and numerous other tauopathies, have repeatedly been shown to be capable of undergoing cell-to-cell transfer and propagate aggregate pathology in a prion-like fashion in experimental models of disease ([@R170]; [@R462]). Nonetheless, in contrast to α-syn fibrils in PD which we described above, AD and other tauopathies do not exhibit the distinct preference for olfactory pathways ([@R55]). Why there are differences between α-syn and tau aggregates regarding preferred anatomical pathways for propagation, despite both types of pathology affecting the olfactory pathways, is presently unclear. One possibility is that the site of initial misfolding events differs between the disorders, with the OB being a stronger candidate in PD than in AD. Another option is that elements of the underlying cell biology of the neuron-to-neuron transfer differ between α-syn and tau aggregates in ways that are not yet understood. Furthermore, some tauopathies primarily affect glial cells ([@R97]), which can explain that the spreading pattern does not follow neural pathways. However, this still does not account for why the pattern of NFT propagation in AD does not strictly follow axonal pathways in the olfactory system ([@R55]).

The progression of Aβ plaques in the brain is less predictable than that of NFTs, and data regarding the involvement of the olfactory system are subject to a lot of variance. Braak et al. described the progression of senile plaques in three stages (A, B, and C), mainly observed in cortical regions. Amyloid plaques are first present in the basal frontal, temporal, and occipital cortices during stage A. Plaques then progress to isocortical areas (sensory, motor, and visual cortices excluded) at stage B, and finally reach the primary isocortical areas and the striatum, thalamus, and hypothalamus notably ([@R53]). The Thal classification system of amyloid plaques comprises 5 stages. Stage 1 involves isocortical regions, progressing then to allocortical regions in stage 2 (entorhinal cortex, amygdala, insular and cingulate cortex, and hippocampal formation). Stage 3 involves subcortical nuclei (striatum, thalamus, hypothalamus notably). Ultimately, amyloid plaques develop in brainstem structures (substantia nigra, medulla oblongata, colliculi, red nucleus) at Thal stage 4 and the pons (LC, raphe nucleus) at stage 5 ([@R436]).

Amyloid plaques are rarely detected in early stages (tau Braak staging) of AD, because patients exhibiting tau inclusions did not all show amyloid plaques ([@R191]; [@R250]; [@R399]; [@R422]), leading to the idea that tau pathology precedes Aβ pathology, an idea still debated ([@R357]). Neuritic plaques have been found in the OB and AON in some studies ([@R93]; [@R250]), while others never detected them in the OB ([@R17]; [@R444]). Finally, central olfactory regions are involved in confirmed cases of AD ([@R372]).

Aβ and tau pathology progress differently during the course of AD ([@R357]). As AD develop, the density of these pathologies increases. Although a peripheral brain structure, the OE also is impacted pathologically during the progression of AD. In one study ([@R15]), Aβ was present in the OE of 71% of AD cases but only in 22% of normal control cases. Paired helical filament tau was also elevated in AD versus control cases.

There are a limited number of studies in humans on the cellular and molecular mechanisms underlying olfactory dysfunction. For example (and as mentioned above), in aged individuals without MCI or AD, olfactory dysfunction is related to the level of AD pathology, including Aβ plaques and NFTs ([@R478]).

Severe cell loss occurs in many brain regions in AD. Patients exhibit severe MC loss in the OB before the clinical symptoms emerge ([@R422]) and in the entorhinal cortex when patients exhibit the mildest clinically detectable dementia ([@R175]). However, it is unclear whether the cell loss is a consequence of the accumulating pathology. Neuromodulatory systems are also severely affected in AD, with 30--90% cholinergic cell loss in the nucleus of Meynert ([@R472]) and severe noradrenergic cell loss in the LC (([@R296]) for review), structures both implicated in Minimal Cognitive Impairment (MCI) ([@R14]). Neuronal death has also been described in the hippocampus ([@R253]). In brief, neuronal death in olfactory regions and neuromodulatory systems could, and are likely to, contribute significantly to olfactory deficits in AD.

4.3. Other neurodegenerative diseases {#S18}
-------------------------------------

Among the diseases that have mild or no olfactory deficits, MSA is the only one with pathological inclusions in olfactory regions ([@R238]; [@R444]). Although neuronal α-syn inclusions are present in MSA ([@R101]), the main pathological hallmark is the presence of glial cytoplasmic inclusions (GCIs), which are mainly composed of aggregated α-syn, and are found in oligodendrocytes of the putamen, the substantia nigra, the pontine base, inferior olive, and globus pallidus. Consistently, the substantia nigra, caudate nucleus, and the frontal and parietal cortices exhibit neuronal loss, and the putamen and globus pallidus exhibit in addition a loss of oligodendrocytes ([@R388]). A few studies have shown that GCIs are also present in the OB (100% cases), the olfactory tract ([@R107]; [@R157]; [@R251]), and the olfactory tubercle (correlating with the number of GCIs in the OB), but are rarely found in the AON despite severe cell loss in this structure in 57% of cases ([@R251]). The presence GCIs and the severe cell loss in the peripheral olfactory system could play a role in the development of mild olfactory disturbances by altering local neuronal activity.

Other diseases that have more-severe olfactory deficits all exhibit pathological inclusions in the olfactory system. The prion disorder CJD severely affects the olfactory structures, with accumulation of misfolded prion protein PrPS^c^ in the olfactory tracts and cortices (olfactory uncal cortex, prepiriform, periamygdaloid, entorhinal cortices). Regrettably, cell loss has never been investigated specifically in the olfactory system. In two reports, PrPS^c^ was detected to a lesser extent in cilia of ORNs and in basal cells of the OE ([@R430]; [@R494], [@R493]). Smaller amounts of inclusions have also been found in the thalamus, basal ganglia, and cerebellum, and severe neurodegeneration has been observed in widespread brain regions ([@R148]; [@R153]; [@R276]; [@R429]; [@R430]), It is unclear where pathology starts in CJD, but inclusions have been observed in olfactory regions in patients with short disease duration, suggesting that the olfactory system is affected early ([@R430]; [@R494]). Biopsies of the OE have been proposed for diagnosis of CJD ([@R493]). The DMX is also affected in two subtypes of CJDs (MV2 and VV2), which raised the question of a dual-hit hypothesis of propagation in CJDs ([@R493]), akin to what has been proposed for PD ([@R196]).

In ALS, intracytoplasmic inclusions of the protein TDP-43 accumulate in the frontotemporal cortex and subcortical regions ([@R329]), brainstem, and spinal cord ([@R147]). These inclusions are associated to severe loss of motor neurons ([@R63]; [@R221]) and the degeneration and atrophy of many central brain regions ([@R36]; [@R63]; [@R147]; [@R338]; [@R416]; [@R461]). A recent study investigated olfactory regions and showed that TDP-43 inclusions affect the secondary olfactory centers (hippocampus and orbitofrontal cortex), the primary olfactory cortex (AON, entorhinal and piriform cortex), and the OB ([@R432]). However, the OB seems to be preserved from cell loss in a small study on 3 patients ([@R338]). Reductions in the volume of the amygdala have also been reported ([@R290]; [@R349]). The severity of TDP-43 pathology follows a rostro-caudal gradient, and it was proposed that the pathology would start in the motor cortex, brainstem, and spinal cord and spread to the hippocampus ([@R64]; [@R147]). Thus, olfactory regions could also be involved in the latest stages of ALS, meaning that the progression would follow a direction opposite to the direction of pathology progression proposed for PD.

In FTD, Pick's bodies (tau inclusions) are predominantly found in the cerebral cortex ([@R169]). Pick's bodies are also found in many cells of the AON and in a lesser extent in the OB (MCs and TCs) and olfactory tubercle ([@R490]). NFTs (8 cases out of 11) and amyloid deposits (3 cases out of 11) were observed in the OB ([@R323]) and might be associated with its atrophy ([@R323]; [@R491]), but they were reported to be absent from one FTD case in another study ([@R490]). Finally, FTD is associated with severe cell loss in the neocortex, hippocampal region and brainstem, akin to HD ([@R110]; [@R241]; [@R364]; [@R390]; [@R401]).

Studies of HD have never investigated pathology and cell loss in anterior olfactory structures, despite olfactory deficits occurring early in the course of the disease. Inclusions of mutated huntingtin protein develop markedly in the midbrain and the cortex during early stages of the disease ([@R16]; [@R459]). "Neuropathological alterations" then appear in the brainstem, amygdala, and cerebellum ([@R459]). Curiously, NFTs are described in atrophied entorhinal cortex, as well as in the hippocampus, frontal and parietal lobe, amygdala, thalamus, midbrain, and locus coeruleus of HD patients, and senile plaques are present in the frontal temporal and piriform cortex (reviewed in ([@R177])). The presence of pathology in the piriform cortex and the amygdala could be responsible for the severe olfactory dysfunction in HD.

Many neurodegenerative diseases show pathological hallmarks characteristic of another disease: NFTs in PD ([@R209]; [@R213]; [@R225]; [@R268]), DLB, and FTD ([@R323]; [@R444]), and α-syn inclusions in AD ([@R188]; [@R314]). These occurrences led to the idea that a misfolded protein could be a template for the aggregation of a different protein (cross-seeding) ([@R314]). The first evidence of direct cross-seeding of tau by Aβ trimers was recently published ([@R407]) and, as mentioned above, it has been suggested that that α-syn fibrils can cross-seed tau ([@R181]). However, whether such cross-seeding occurs in vivo for other proteins is still controversial, and it is unclear if a third protein (or more) is required or if direct cross-seeding occurs.

In summary, alteration of olfactory perception occurs as part of neurodegenerative diseases, accompanied by pathology and cell loss in the primary, secondary, and tertiary olfactory structures. We propose that the OE, OB, and AON are particularly vulnerable to injuries and dysfunction. Unfortunately, these regions have only rarely been investigated in diseases other than AD and PD.

5. Why are the olfactory epithelium and olfactory bulb so vulnerable? {#S19}
=====================================================================

Directly accessible from the external environment, the OE is exposed to a variety of environmental insults. While the OE has several barriers to such insults, ranging from physical to enzymatic and immune defenses ([Fig. 1](#F1){ref-type="fig"}), these barriers deteriorate with age, rendering them more permeable to xenobiotics and toxins. We hypothesize that external agents (bacteria, viruses, toxins, airborne pollutants, micro- and nanoparticles) might trigger disease via the OE. Either these agents gain access to the brain through the OE and spread along its associated connections, or they trigger protein misfolding locally in the OE and OB that, in turn, leads to prion-like propagation of protein aggregates via olfactory pathways. Beyond an anatomically vulnerable location, the OE and the OB have certain characteristics that could make them vulnerable to disease. Our hypothesis does not exclude the existence of other neuronal systems that exhibit inherent properties that could render them vulnerable (e.g. long axons affected early in ALS). Nor does our hypothesis exclude that other neuronal system also are exposed to external agents that potentially can trigger pathological conversion of proteins (e.g. enteric nerves in PD). However, in this review we have chosen to focus on the potential role of the olfactory system in neurodegenerative diseases. Therefore, in the following section, we will review evidence that the OE and OB are sensitive to inflammation and to oxidative stress; express high levels of proteins involved in neurodegenerative diseases; and exhibit intrinsic neural activity that could make them sensitive to cell stress and promote protein accumulation.

5.1. Increased permeability of olfactory epithelium due to infection, mutation, or normal aging {#S20}
-----------------------------------------------------------------------------------------------

Among external factors that deteriorate the OE are respiratory pathogens and external insults that impair tight junctions between the epithelial cells of the nasal epithelium and the OE, increasing epithelial permeability to external substances ([@R106]). The loss of detoxifying enzymes in nasal mucus can also affect the permeability of the OE ([@R258]). People with mutations of the cytochrome P450-CYP2D6-debrisoquine hydroxylase, involved in detoxification of xenobiotics, show increased risk of developing PD ([@R143]; [@R415]), possibly due to a compromised barrier in the OE ([@R122]; [@R198]).

Also, the OE dramatically changes with age; the ORNs can undergo necrosis and the OE becomes thinner ([@R18]). Although not demonstrated in the OE, misfolded α-syn can perturb the expression of tight junction proteins ([@R255]) and could contribute to increased permeability of the OE. Other changes in the OE with aging, include a decrease in calbindin-D28k expression, which potentially makes neurons more vulnerable to calcium overload and excitotoxicity ([@R486]). Furthermore, monoaminergic innervation of the OE decreases ([@R85]), which affects mucosal secretions. Nasal mucociliary clearance is also less effective in the elderly ([@R387]). Thus, as a consequence of infection, environmental stresses, and aging, the OE becomes more vulnerable to pathogen entry.

5.2. The olfactory mucosa and bulb, a gateway to the brain for viruses {#S21}
----------------------------------------------------------------------

Numerous studies have tentatively linked the exposure to pathogens, particles, or pesticides with increased risk of developing PD. Hawkes et al. proposed a dual-hit hypothesis: PD could be triggered by the entry and the propagation of a viral agent through both the OE and the enteric mucosa. Essentially, the viral agent would be inhaled and then access the gut via the swallowing of saliva and nasal mucus, and could cause nervous system pathology while spreading along olfactory pathways and enteric nerves that access the central nervous system ([@R62]; [@R124]; [@R196]). As an alternate model, it was suggested later that this neuropathological agent could trigger pathology at the entry site where assemblies of misfolded α-syn could accumulate in neurons in the OB and in enteric nerves of the gut wall, and misfolded α-syn itself would spread in a prion-like manner to connected brain regions ([@R69]; [@R164]; [@R271]). These two hypotheses are consistent with the appearance of olfactory deficits and of gastrointestinal dysfunction in people before they develop PD or DLB, i.e., during the prodromal stage ([@R299]; [@R302]).

Viruses (and toxins, see further below) can reach the brain through the ORNs ([@R25]; [@R106]; [@R124]; [@R355]; [@R440]; [@R450]) (reviews; ([@R212]; [@R450])). By penetrating ORNs, they can travel via axonal transport, within the olfactory ensheathing cells, or within the perineural space, and pass through the cribriform plate to access the subarachnoid space ([@R106]). Viruses, for example, can migrate from the OB to other brain regions (for a review, see ([@R106]). The trigeminal nerve can also be a route of entrance to the central nervous system from the oral, nasal cavity and from the cornea ([@R106]). PD risk is increased following exposure to certain viruses ([@R484]; [@R496]), and viral infections can also affect α-syn. Infection of mice with H5N1 virus triggers the phosphorylation and aggregation of α-syn ([@R226], [@R227]). Interestingly, though, α-syn expression in neurons inhibits viral infection ([@R35]), so an increase in α-syn expression could be a defense against viral infection that inadvertently increases PD risk. It has also been shown that antibodies to Epstein Barr Virus can cross-react with α-syn ([@R481]), which has been hypothesized to promote its aggregation in the olfactory system and gut in people who later develop PD ([@R482]).

5.3. Xenobiotics and airborne pollutants affect protein aggregation {#S22}
-------------------------------------------------------------------

PD risk is also higher after exposure to several agents that can be inhaled, e.g. pesticides ([@R25]; [@R67]; [@R91]; [@R385]; [@R435]), pollutants ([@R45]), micro- or nanoparticles ([@R91]), organic solvents ([@R67]), and metals ([@R67]; [@R91]; [@R154]). In addition, exposure to the bacterial amyloid protein curli promotes α-syn aggregation ([@R84]). Exposure to environmental toxins, some of which can be inhaled and therefore can gain access to the olfactory system, has been associated with increased PD risk ([@R172]). Laboratory studies have provided insight into mechanisms that might contribute to the triggering of PD following toxin exposure. For example, in vitro experiments have shown that, under certain conditions, metals (e.g. copper) directly induce conformational changes in α-syn and can promote α-syn fibrillization (similar to pesticides ([@R339]; [@R447]; [@R458])) or increase in α-syn expression ([@R483]). Recent work in mice has shown that systemic exposure to the fungicide maneb and the herbicide paraquat can increase formation of α-syn radicals in the brain, which can promote aggregation of the protein ([@R257]). Furthermore, systemic injection in rats with the mitochondrial complex I inhibitor rotenone, which is used as a pesticide, insecticide and fish killer, was recently found to lead to increased levels of phosphorylated and aggregated α-syn ([@R118]) These recent reports on effects of environmental toxins are in agreement with earlier findings ([@R224]) that oxidative damage to ([@R343]) and mitochondrial dysfunction ([@R359]) can promote a-syn aggregation.

Beyond direct effects on α-syn, airborne pollutants, environmental agents and xenobiotics that can penetrate the central nervous system through the olfactory route, producing undesirable effects in the brain such as inflammation, oxidative stress ([@R45]; [@R86]), increased apoptosis ([@R91]), and dysfunction of mitochondria and proteasome ([@R385]). All of these effects could affect neuronal function and protein aggregation.

The risk of developing AD is increased by exposure to pesticides ([@R25]; [@R67]; [@R91]; [@R385]; [@R435]), viruses ([@R24]; [@R192]; [@R277]; [@R496]), pollutants ([@R45]), and metals that are able to stimulate Aβ production ([@R67]; [@R91]). Few studies have investigated DLB, but exposure to metals has been implicated as a risk ([@R298]). MSA has been linked to metal and organic solvent exposure ([@R451]), environmental toxins, and pollutants ([@R189]), but a link to pesticides is controversial ([@R94]; [@R451]). ALS is also associated with pesticides (([@R25]), metals ([@R51]; [@R232]; [@R424]; [@R435]), solvents, viruses ([@R496]), and possibly to pollutants ([@R293]). CJD is obviously related to infection by the misfolded protein PrPsc itself. Animal models of PrPSc spread show that the nasal route is more efficient for prion infection than the gastric route ([@R247]) and that in infected hamsters, prions can be released in nasal fluid ([@R42]). Further, OE damage favors the release of prions in the nose ([@R43]).

5.4. Myelination and energy expenditure {#S23}
---------------------------------------

Another possible vulnerability to neurodegenerative disease is the myelination level of neuronal populations in the brain. The absence of myelination requires a higher energy expenditure to convey neural impulses ([@R58]; [@R331]; [@R449]) and make the cells more susceptible to oxidative stress. Myelination, on the other hand, might protect the cells better against pathogens ([@R62]) and against aberrant axonal sprouting ([@R76]; [@R79]; [@R452]). Braak et al. have proposed that neurons that are unmyelinated or sparsely myelinated, have long, thin axons, and have high energy turnover are more susceptible to disease ([@R52]; [@R58]). The ORNs could thus be particularly sensitive, because they fit these three criteria ([@R126]; [@R327]). The MCs and TCs also possess long axons but are often myelinated ([@R437]). It is conceivable that MCs and TCs are thus more resistant to developing inclusions, which would be consistent with the observation of more severe pathology in AON cells than in the mitral cells of OB ([@R445]). It is also notable that this lack of myelin coincides with a reduced integrity of the blood brain barrier at the level of the olfactory bulb ([@R308]).

5.5. Sensitivity of the OE and OB to inflammation and oxidative stress {#S24}
----------------------------------------------------------------------

Many xenobiotics and particles that can penetrate the brain through the OE are known to trigger reactive oxygen species (ROS) production and inflammatory reactions, similar to the effects of misfolded proteins. As an interface between the external environment and the brain, the OE and OB are particularly subject to inflammatory reactions. As mentioned earlier, the OB and olfactory nerve hosts selective dense populations of microglia that act to prevent particles and pathogens from penetrating the brain. The microglia of the OB show more rapid and higher levels of activation for longer periods (lasting for months) relative to microglia in other regions of the brain ([@R259]). OB microglia can also be activated by injury or infections occurring in distant sites and might play a role of sentinel for the whole brain ([@R259]; [@R417]). Inflammation in the OB is affected by changes in neurotransmitters (a decrease in noradrenaline release by the locus coeruleus increase inflammation level, for example) ([@R149]; [@R206]; [@R394]). Also, activated microglia release proinflammatory cytokines and ROS that can damage cells ([@R425]). These proinflammatory cytokines and ROS ([@R141]; [@R374]), as well as changes in neurotransmitters release ([@R236]) can disrupt the blood--brain barrier, thus facilitating the penetration of xenobiotics and particles into the brain.

While aggregated proteins (α-syn, Aβ, PrP, SOD1, and tau) induce microglial activation ([@R142]; [@R206], [@R207]; [@R274]; [@R495]), inflammation can in return promote the aggregation of some prion-like proteins in the brain and peripheral cells ([@R100]; [@R203]; [@R248]; [@R266]; [@R427]; [@R456]). Similarly, excessive ROS production increases inflammation and favors prion-like protein aggregation ([@R5]; [@R48]; [@R98]; [@R306]; [@R361]; [@R367]; [@R408]; [@R413]), which in return increases oxidative stress ([@R5]; [@R48]; [@R361]; [@R367]).

Hence, a vicious feed-forward loop of inflammation, involving a complex interplay of ROS production and protein aggregation, could play an important role in the pathogenesis of prion-like diseases ([@R269]; [@R367]), and anterior olfactory regions could be particularly vulnerable due to the presence of highly sensitive microglia and a blood--brain barrier that is easily compromised.

5.6. Level of expression of misfolding-prone proteins in the olfactory epithelium and bulb {#S25}
------------------------------------------------------------------------------------------

### 5.6.1. α-syn {#S26}

Genetic forms of PD have taught us that the simple elevation of α-syn expression by gene duplication can cause disease ([@R414]). One can imagine that a transient increase in α-syn expression could also contribute to the initiation of disease and that brain regions that naturally express higher levels of α-syn might be more prone to developing α-syn pathology triggered by stochastic events. Another possibility is that an increase in α-syn expression could be a physiological response of an injured cell trying to maintain correct synaptic function. As mentioned above, a local increase in α-syn expression has been suggested as a defense mechanism against viral infection, because α-syn expression was shown to restrict RNA viral infections in the brain ([@R35]).

In humans, only a few studies have defined the normal spatial pattern of expression of α-syn, and those focused only on few brain regions (olfactory brain structures were not investigated). More α-syn was reported in the cell body of neurons in the temporal and frontal cortex, CA2 and CA3. In healthy humans, high levels of α-syn, exacerbated by aging, and increased mRNA for proteins that are associated to LBs were detected in the substantia nigra relative to other brain regions ([@R95]; [@R155]; [@R318]). When comparing different diseases (PD, DLB, and AD versus healthy controls), no difference in α-syn mRNA levels was found, but protein levels were lower in DLB and PD relative to controls in some brain regions ([@R362]). Those studies investigated the brains of patients with severe disease, so the results might not reflect the α-syn levels in early phases of the disease. One study investigated the presence of α-syn in the olfactory mucosa in humans and found that α-syn is most abundant in basal cells and ORNs but is also expressed in sustentacular cells of the OE and in the Bowman's glands ([@R139]). In mouse, the pattern of α-syn in the brain was studied in depth by [@R431]. In this study, brain regions that typically are affected early in PD contain high amounts of α-syn. The OB (GL), DMX, and substantia nigra pars compacta display high amounts of α-syn in the neuronal soma. Other layers of the OB (external plexiform and granule cell layers), the AON, the LC, the central and basolateral amygdala, piriform, entorhinal cortices, and the hippocampus display moderate to high amounts of α-syn within presynaptic terminals ([@R431]).

### 5.6.2. APP {#S27}

APP is a large membrane-bound glycoprotein that forms the Aβ peptide when metabolized. The APP transcript is highly expressed in neurons of the associative neocortex and hippocampus ([@R330]), and APP protein is dense in the cortex, particularly in the entorhinal, occipital cortex, and superior temporal gyrus ([@R81]). No data are available regarding this protein's expression in olfactory structures in human. In rats, APP mRNA is found in the cortex, the hippocampus, the piriform cortex, olfactory tubercle, and cerebellum ([@R309]). The APP protein is highly expressed in the OB, in the nerve layer, EPl and GL of adult rats, and damages to the OE exacerbate the expression of APP in the OB ([@R423]). Unfortunately, the expression of APP in the OE and AON was not investigated.

### 5.6.3. Tau {#S28}

Tau expression has not been investigated in olfactory structures in humans. The only studies exploring olfactory regions were conducted in rats, and showed that tau is highly expressed in the ORNs and in the axons of the ORNs in the OB ([@R398]), and is also present in mitral cells and interneurons of the OB ([@R457]). Tau mRNA has been found in cortical areas in humans ([@R330]), and the protein is highly expressed in the cortex, particularly the entorhinal, occipital cortex, the frontal cortex, and the superior temporal gyrus; it is moderately expressed in the hippocampus ([@R81]; [@R442]; [@R443]). The recent transcriptome-wide microarray study by Freer et al. revealed elevated levels of tau and Aβ in the brain regions that are affected early in AD (olfactory regions were not investigated). In addition, Freer found that proteins involved in homeostasis are differentially expressed in AD: aggregation protectors are downregulated while aggregation promoter proteins are upregulated ([@R155]). This suggests that changes in the pattern of expression of proteins involved in homeostasis within brain regions that express more of those proteins might make those regions more vulnerable to developing disease.

### 5.6.4. PrP {#S29}

The regional location of PrP^c^ in human brain has not been studied in detail. Kuczius et al. describe its expression in the frontal neocortex, thalamus, hippocampus, and cerebellum ([@R256]), but olfactory structures were not assessed. In the mouse, a strong immunoreactivity for PrP^c^ is observed in the cerebral cortex (piriform and cingulate), striatum, ventral pallidum, OB, and hippocampus ([@R40]). PrP^c^ is also present in the mouse substantia nigra ([@R40]).

In conclusion, the spatial patterns of expression of α-syn, APP, tau, and PrP remain unclear, especially in humans. No data are available for TDP-43, and for other proteins, many brain structures have not been investigated. For brain regions that express high levels of a prion-like protein, any event that disturbs the balance between protein level and protein clearance might contribute to the development of pathology. Another key element of protein expression is the intrinsic neural activity of brain regions.

5.7. Intrinsic neural activity and prion-like proteins {#S30}
------------------------------------------------------

Here we discuss the observations of changes in neural activity in the OE and OB during disease and their consequences. The level of protein expression can be modulated by neuronal activity, exaggerating the pathological accumulation of protein. As a consequence, high levels of pathological proteins might also disturb cellular function and lead to aberrant neuronal activity. This is particularly interesting in the context of prion-like propagation, where an increase of neuronal activity in one brain region could lead to increase release of prion-like protein at the synaptic level into downstream structures, thus contributing to the propagation of pathological proteins within the brain.

Neuronal hyperactivity increases Aβ production via endocytic pathways (see ([@R421]) for a review) and favors the release of Aβ in interstitial fluid, which is dependent on synaptic activity ([@R96]; [@R237]). Such events take place at early stages of AD, when the degradation of Aβ is decreasing ([@R421]). On the other hand, high levels of Aβ promote neuronal hyperactivity, due to a decrease in synaptic inhibition and increased incidence of action potential bursts ([@R73]). Thus, a vicious cycle between the production of Aβ, its release, and changes in neuronal activity of neurons probably contributes to AD pathogenesis. Because AD is associated with increased risk for epileptic seizures ([@R73]; [@R421]), particularly in people with early-onset dementia ([@R9]), the interaction between neuronal hyperactivity and Aβ in AD has been well studied, mainly in hippocampal regions. In AD, neuronal hyperactivity occurs both in large brain networks leading to epileptiform activity and in localized foci. Neuronal hyperactivity occurs at early stages of AD, when epileptiform activity is associated with high level of Aβ ([@R73]). In healthy elderly individuals, high levels of amyloid deposits have been linked to aberrant neuronal activity by fMRI ([@R419]). The presence of Aβ and tau pathology in central and peripheral brain regions suggests that the neural basis for olfactory dysfunction in AD is not simply dysfunction in one structure at one stage of processing, but dysfunction at numerous stages of processing, from the initial binding of the odorant to the OR to the more central cortical processing of perceptually relevant aspects of olfaction. ORNs of the OE display spontaneous firing in the absence of any odor stimulus in wild-type mice ([@R233]). Some findings support the notion that the olfactory system, including the OB and piriform cortex, engages in sparse coding of odor information wherein only a minimal number of cells are needed to be active and to function with the optimal level of excitation and inhibition ([@R109]; [@R353]; [@R375]). Modeling evidence suggests that the spare coding of odors in the OB uses low energy and leads to high representational capacity ([@R492]). This type of activity might be particularly perturbed by hyperactive neurons ([@R73]).

Studies in mice have provided some evidence for possible mechanisms of olfactory dysfunction and their influence on neural circuits ([@R77]; [@R88], [@R87]; [@R102]; [@R180]; [@R315]; [@R370]; [@R467]; [@R487]). These studies suggest a crucial role of soluble Aβ for neuronal hyperexitability in the hippocampus and OE ([@R72]; [@R77]). In some cases, alterations in normal neural activity have been reported, including early-life hyperactivity in the OB ([@R467]) that may result in enhanced post-synaptic release of Aβ and other APP metabolites into down-stream structures. Some of these studies have reported aberrations in intrinsic neural activity, including hyper- and hypoactive neural systems in mouse models of AD. The end result of all the proposed mechanisms suggests that AD-associated pathologies and factors associated with them (e.g., cytokines) impair neural function within key olfactory structures, which thereby result in deficits in olfaction.

In synucleinopathies, hyperactivity of neuronal circuits had not been studied extensively, and olfactory circuits have not been explored. One single study investigated network activity in mice overexpressing α-syn and reported changes of network activity in the hippocampus ([@R320]). A high occurrence of myoclonus has been observed in DLB patients, a sign of disturbed neuronal activity; α-syn is suggested to be partially responsible of the hyperactivity of the network ([@R320]). Phantosmia (olfactory hallucinations) could reflect also hypersensitivity of the olfactory network. Phantosmia is believed to be a clinical manifestation of circuit disinhibition, notably following deafferentation due to OE damage and resulting loss of sensory input ([@R208]). Phantosmia has been reported in PD and could also be a symptom of AD, although it is rarely evaluated by physicians ([@R26]; [@R260]; [@R441]). Although not investigated in olfactory structures, neural hyperactivity in PD could be due to an interplay between pathological α-syn and Ca^2+^ flux, potentiating each other ([@R219]; [@R284]; [@R367]).

TDP-43 aggregation and its effect on neuronal activity have never been studied. However, in a model of frontotemporal dementia with Parkinsonism overexpressing human mutated tau, spontaneous epileptic activity and seizures were observed by EEG, as well as hypersensitivity to a GABAa receptor antagonist ([@R162]).

Finally, the loss of PrP^c^ function also contributes to the hyperexcitability of networks in the neocortex and hippocampus, and it can lead to epileptic seizures ([@R463]). Thus, hyperexcitability of neuronal networks might also occur in CJD.

The molecular mechanisms underlying neuronal hyperactivity induced by pathological protein are unclear. Dysfunction in glutamatergic transmission, which leads to excitotoxicity, is involved in many neurodegenerative diseases (for review: ([@R10]; [@R121]). Although not studied specifically in the olfactory system, alteration of glutamatergic transmission by pathological proteins, mutations, or inflammatory mechanisms ([@R27]; [@R205]; [@R340]; [@R351]) could occur in the OE/OB, where glutamatergic cells are particularly vulnerable ([@R445]), and could underlie hyperactivity and excitotoxicity.

6. Conclusion {#S31}
=============

Neuropathological data and olfactory functional measurements support the early involvement of olfactory structures in PD, AD, DLB, HD, and, to some extent, CJD. Pathology and functional alterations are also involved in other neurodegenerative diseases such as MSA and ALS, where the timing of olfactory disturbances is not yet defined. By contrast, in FTD the olfactory network is involved late in the course of the disease, suggesting a spreading mechanism inverted relative to that in PD or DLB. Further work is needed to better understand the involvement of olfactory regions in disease development. Comparisons of propagation patterns between diseases could help determine the spatial origin and etiology of the pathology. For example, in PD, monitoring impairments in olfaction will also allow for better prediction of clinical course (e.g. if a patient is likely to exhibit cognitive decline soon), stratification of patients entering clinical trials, and the possibility to start future disease-modifying therapies before the onset of motor symptoms. Together, the literature reviewed herein support our argument that pathological changes following environmental insults might contribute to the initiation of protein aggregation in the olfactory bulb, which then triggers the spread of the pathology within the brain by a templating mechanism in a prion-like manner.
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α-Syn

:   α-synuclein

Aβ

:   beta-amyloid

AD

:   Alzheimer's disease

AON

:   anterior olfactory nucleus

ALS

:   amyotrophic lateral sclerosis

APP

:   amyloid precursor protein

CBD

:   corticobasal degeneration

CJD

:   Creutzfeldt-Jakob disease

DLB

:   dementia with Lewy bodies

FTD

:   frontotemporal dementia

HD

:   Huntington's disease

iLBD

:   incidental Lewy body disorder

LBs

:   Lewy bodies

MCs

:   mitral cells

MCI

:   mild cognitive impairment

MSA

:   multiple system atrophy

OB

:   olfactory bulb

OE

:   olfactory epithelium

ORNs

:   olfactory receptor neurons

ORs

:   olfactory receptors

PAF

:   pure autonomic failure

PD

:   Parkinson's disease

PSP

:   progressive supranuclear palsy

ROS

:   reactive oxygen species

TCs

:   tufted cells

![Schematic of the olfactory mucosa and different defense mechanisms against pathogens entry and cellular damages by environmental exposure. 1) Bowman's glands secrete the olfactory mucus that contains immune factors, lysozymes, enzymes, antioxidants, and possibly xenobiotic-metabolizing enzymes capable of viral inactivation, detoxification, bacterial degradation, and destruction of pro-inflammatory molecules. 2) The mucus layer in which cilia of olfactory receptor neurons (ORNs) are immersed provides electrical insulation to the neurons and catches particles and odorants in suspension in the air. 3) Sustentacular cells maintaining water and salt balance in the mucus and metabolize xenobiotics. 4) Dense network of tight junctions between sustentacular cells and ORNs, and between the serous cells of Bowman's glands, prevent pathogens from infiltrating the olfactory epithelium (OE). 5) Sustentacular cells might phagocytose debris and dying cells. 6) Damaged ORNs are constantly replaced by newborn ORNs, differentiating from the globose cells that derive from the horizontal cells. 7) In case of damage to the OE or contamination, neutrophils and macrophages can invade the olfactory mucosa though the lamina propria. 8) Ensheathing cells protect and electrically isolate the axons of ORNs. 9) Nerve bundles are protected by fibroblasts enveloping them. 10) Microglial population localized in nerve bundles and in external layers of the olfactory bulb is believed to be in a contact state alert.](nihms968009f1){#F1}

###### 

Olfactory perception includes odor detection (lowest perceptible concentration),\[ odor discrimination (distinction of two different odorants), odor identification (naming odors), odor retention memory, and judgment of odor hedonicity (pleasantness). The University of Pennsylvania Smell Identification Test (UPSIT) and cross-cultural UPSIT-derived tests are the most common methods used to assess olfaction in neurodegenerative diseases

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                                     Olfactory deficits                                                      Prevalence                                                                                                   Onset                                                                                                                                                                                                                                                                                                                                              
  ----------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------------- -------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------
  Synucleinopathies                                           PD                                                                      Severe (UPSIT40 = 15--20) ([@R47]; [@R130]; [@R123]; [@R138]; [@R243]; [@R348]; [@R410]; [@R411]; [@R466])   Severe ([@R122]; [@R129]; [@R252];\                  Severe ([@R252])                                             Severe ([@R129]; [@R252]; [@R217]; [@R497]; [@R130])                 Severe ([@R217];\                                 None ([@R46])                          90% ([@R122],[@R123]; [@R129])                                     4--6 years before clinical diagnosis ([@R122],[@R123];\
                                                                                                                                                                                                                                                   [@R217];\                                                                                                                                                                              [@R322])                                                                                                                                                    [@R19]; [@R379]; [@R136])
                                                                                                                                                                                                                                                   [@R127]; [@R130])                                                                                                                                                                                                                                                                                                                                  

  DLB                                                         Severe ([@R275]; [@R301]; [@R166]; [@R337]; [@R90]; [@R391]; [@R473])   Mild to severe ([@R275]; [@R166]; [@R473])                                                                   --                                                   Severe ([@R275]; [@R473])                                    --                                                                   Yes ([@R166])                                     41--67% ([@R337]; [@R90])              2.9--9 years before cognitive signs ([@R90])                       

  iLBD                                                        Mild (UPSIT40 = 16--22) ([@R138]; [@R2])                                --                                                                                                           --                                                   Mild ([@R138]; [@R2])                                        --                                                                   --                                                --                                     Early (considered by authors as precursor stage of PD) ([@R138])   

  MSA                                                         Mild to slight (UPSIT40 = 27--34) ([@R466]; [@R163]; [@R411])           Mild ([@R325]; [@R328])                                                                                      Slight ([@R1])                                       Mild to slight ([@R466]; [@R1]; [@R163]; [@R426]; [@R411])   --                                                                   --                                                20--53% ([@R163]; [@R174]; [@R325])    --                                                                 

  MPTP-induced parkinsonism[\*](#TFN2){ref-type="table-fn"}   Mild or absent (UPSIT40 = 34) ([@R135])                                 None ([@R135])                                                                                               --                                                   Mild or absent ([@R135])                                     --                                                                   --                                                --                                     --                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  PAF                                                         Mild to severe (UPSIT40 = 19--22) ([@R163]; [@R174]; [@R411])           --                                                                                                           --                                                   Mild to severe ([@R163]; [@R174]; [@R411])                   --                                                                   --                                                83% ([@R163]; [@R174])                 --                                                                 

  Tauopathies (primary and secondary)                         AD                                                                      Severe UPSIT40 = 18--23 ([@R453]; [@R92]; [@R317]; [@R311])                                                  Mild to severe ([@R301]; [@R304]; [@R120]; [@R22])   Severe ([@R289]; [@R304]; [@R120])                           Severe ([@R289]; [@R304]; [@R120]; [@R22])                           None/only for pleasant odors ([@R384]; [@R234])   Severe ([@R366]; [@R332])              22.5% anosmic ([@R337])                                            Early (in MCI, deficit in detection and identification) ([@R120])

  PSP[\*](#TFN2){ref-type="table-fn"}                         Mild to none (UPSIT40 = 22--26) ([@R466]; [@R410]; [@R130])             None ([@R130])                                                                                               --                                                   Mild or absent ([@R466]; [@R410]; [@R130])                   --                                                                   --                                                28% ([@R466])                          --                                                                 

  CBD[\*](#TFN2){ref-type="table-fn"}                         Mild to none (UPSIT40 = 27) ([@R466])                                   --                                                                                                           None ([@R289])                                       Mild ([@R289]; [@R341])                                      --                                                                   --                                                68% ([@R341])                          --                                                                 

  FTD[\*](#TFN2){ref-type="table-fn"}                         Mild (UPSIT40 = 22--23) ([@R341]; [@R300])                              --                                                                                                           None ([@R289])                                       Mild ([@R289]; [@R341]; [@R211])                             --                                                                   --                                                95--96% ([@R289])                      --                                                                 

  TDP-43 proteinopathy                                        ALS                                                                     Mild (UPSIT40 = 25--30) ([@R200]; [@R144])                                                                   --                                                   --                                                           Mild ([@R432])                                                       --                                                --                                     75.7% ([@R432])                                                    --

  Huntingtin proteinopathy                                    HD                                                                      Mild to severe (UPSIT40 = 21--25) ([@R150]; [@R311]; [@R30])                                                 Mild to severe ([@R22]; [@R311]; [@R265])            Mild to severe ([@R265]; [@R187])                            Mild to severe ([@R22]; [@R150]; [@R311]; [@R30]; [@R265]; [@R75])   Yes ([@R310])                                     None/yes ([@R187]; [@R333]; [@R350])   100% ([@R311])                                                     Early (prior to motor and cognitive dysfunction) ([@R350])

  Prion disease                                               CJD[\*](#TFN2){ref-type="table-fn"}                                     Yes ([@R368])                                                                                                Yes ([@R368])                                        --                                                           --                                                                   --                                                Yes ([@R368])                          --                                                                 Early (months) ([@R368])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

{[@R132], [@R134], [@R133]}, and can be used to compare the severity of olfactory deficits in different diseases. Abbreviations: PD: Parkinson's disease; iLBD: incidental Lewy body disorder; DLB: dementia with Lewy bodies; AD: Alzheimer's disease; MSA: multiple system atrophy; PSP: progressive supranuclear palsy; FTD: frontotemporal dementia; ALS: amyotrophic lateral sclerosis; PAF: pure autonomic failure; HD: Huntington's disease; CJD: Creutzfeldt-Jakob disease.

Limited number of patients studied. --- Data not reported/not studied.
